Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Downgrades Relmada Therapeutics to Neutral

Guggenheim Downgrades Relmada Therapeutics to Neutral

Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.

byBenzinga Newsdesk

October 14, 2022

1 minute read

Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.

Clear Secure Has Much To Look Forward To, Including AMEX Partnership, Says Analyst

By Anusuya Lahiri

February 23, 1:23 PM

Needham analyst Joshua Reilly initiated coverage on Clear Secure Inc (NYSE: YOU) with a

AXP

DiDi Fined $1.2B In China: Is The Company Finally Out Of Rough Waters?

By Bhavik Nair

July 21, 4:07 AM

China has fined ride-hailing app DiDi Global Inc – ADR (OTC: DIDIY) $1.2 billion for violating its data security law, cyber security law and personal information protection law. The decision has brought to conclusion a year-long investigation into the firm.

BABA